A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients
About this study
This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation
- Condition
- HER2-positive Breast Cancer, Trastuzumab Deruxtecan
- Tested
- T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
- Sponsor
- Blokhin's Russian Cancer Research Center
Who can join
- Age
- 18 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 80 years
- Study condition: HER2-positive Breast Cancer, Trastuzumab Deruxtecan
- Patients aged over 18 years old.
- Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- Patients has received Trastuzumab Deruxtecan
- Available medical history.
Exclusion 2
- Incomplete medical history.
- Pregnancy or breast-breeding
Where
1 site, 1 recruiting
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Moscow, Russia
Contact
-
Elena Artamonova
+7 (499) 444-24-24 tatiana.titovadoc@gmail.com
Potential match only. Final eligibility is determined by the study team.